4-tert-Butylcyclohexanecarboxylic Acid (cis- and trans- mixture)>98.0%(GC)(T)25g

2-(3',5'-DIFLUORO-[1,1'-BIPHENYL]-2-YL)ETHANAMINE HYDROCHLORIDE, 95.0%, 250mg

5-(4-Ethylphenyl)-5-oxovaleric acid, 95.0%, 25g

Colonne capillaire GC ROTI®Cap-1701, 25 m, 0,32 mm, 0,25 µm, 1 pièce(s)

6-(Aminomethyl)quinoline>98.0%(GC)(T)200mg

(5-Fluoro-2,3-dihydrobenzofuran-4-yl)methanamine, 98%, 5g

1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde, 97.0%, 100mg

Ethyl 4-methylpiperidine-4-carboxylate, 95.0%, 5g

6,7-Dihydroimidazo[1,5-a]pyridin-8(5H)-one, 95.0%, 5g

(2S,3R,4S,5R)-2,3,4,5-Tetrahydroxy-6-oxohexanoic acid hydrate, 95.0%, 5g

Epigoitrin, 97%, 10mg

4-Piperidinecarboxylic acid t-butyl ester hydrochloride, 95.0%, 25g

N-Phenylnicotinamide hydrochloride, 95+%, 250mg